Please download the dossier by clicking on the dossier button x
×

KINASE INHIBITORS

  • US 20090291937A1
  • Filed: 10/31/2008
  • Published: 11/26/2009
  • Est. Priority Date: 11/02/2007
  • Status: Active Grant
First Claim
Patent Images

1. A compound represented by structural formula I or IA:

  • or a pharmaceutically acceptable salt thereof wherein;

    A and A′

    are independently —

    N—

    or —

    C(R+)—

    ;

    ring B is five- or six-membered saturated carbocyclic or heterocyclic ring;

    R1 is halogen, —

    CN, —

    NO2, or -T1-Q1;

    T1 is absent or a C1-10 aliphatic wherein one or more methylene units of T1 are optionally and independently replaced by G wherein G is —

    O—

    , —

    S(O)p

    , —

    N(R′

    )—

    , or —

    C(O)—

    ; and

    T1 is optionally and independently substituted with one or more JT1;

    Q1 is absent or a 3-8 membered saturated, partially saturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from the groups consisting of O, N, and S, or an 8-12 membered saturated, partially saturated, or fully unsaturated bicyclic ring having 0-5 heteroatoms independently selected from the group consisting of O, N, and S, wherein Q1 is optionally and independently substituted with one or more JQ1;

    wherein when R1 is T1-Q1, then T1 and Q1 are not both absent;

    R2 is —

    H, —

    (CR++2)nCN, —

    (CR++2)nN(R)2, —

    (CR++2)nOR, —

    (CR++2)nC(O)N(R)2, or C1-10 aliphatic optionally substituted with one or more halogen, phenyl, OR*, or N(R*)2;

    each R3 and R4 independently are —

    H, halogen, C1-10 aliphatic, heterocyclyl, heterocyclylalkyl, aryl, or aralkyl, wherein R3 and R4 are optionally and independently substituted with one or more selected from the group consisting of C1-10 alkyl, halogen, —

    CN, —

    NO2, —

    N(R*)2, —

    S(O)pR*, —

    S(O)NR*, —

    C(O)N(R*)2, —

    NR*C(O), —

    OC(O)N(R*)2, —

    N(R*)C(O)OR*, —

    N(R*)C(O)N(R*)2 and —

    OR*;

    or R3 and R4 taken together with the carbon to which they are attached form C═

    O, or a 3-8 membered saturated, partially saturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from the groups consisting of O, N, and S, wherein the ring is optionally and independently substituted with one or more selected from the group consisting of ═

    O, ═

    S, ═

    N—

    R*, C1-10 aliphatic, C1-10 haloaliphatic, halogen, —

    CN, —

    NO2, —

    N(R*)2, —

    S(O)pR*, —

    S(O)pNR*, —

    C(O)N(R*)2, —

    NR*C(O), —

    OC(O)N(R*)2, —

    N(R*)C(O)OR*, —

    N(R*)C(O)N(R*)2 and —

    OR*;

    each R5 and R6 are independently —

    H, halogen, C1-10 haloaliphatic, or C1-10 aliphatic;

    each R7 is independently C1-10 haloaliphatic, C1-10 aliphatic, halogen, —

    NO2, —

    (CR++2)nCN, —

    (CR++2)nN(R**)2, —

    (CR++2)nOR**, or —

    (CR++2)nC(O)N(R**)2, or two R7 groups together with the carbon to which they are attached form C═

    O;

    each JT1 is independently halogen, —

    OR̂

    , —

    N(R̂

    )2, or —

    CN;

    each JQ1 is independently halogen, C1-10 alkyl, C1-10 haloalkyl, —

    OR″

    , —

    N(R″

    )2, —

    CN, —

    NO2, —

    S(O)pR″

    , —

    S(O)pNR″

    , acyl, carbalkoxyalkyl, or acetoxyalkyl;

    each R+ is independently —

    H, halogen, or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    each R++ is independently —

    H or halogen;

    each R′

    is independently —

    H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    each R̂

    is independently —

    H, C1-10 alkyl, or aralkyl wherein each R̂

    is optionally and independently substituted with up to five halogen groups;

    each R″

    is independently —

    H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    each R is independently —

    H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    each R* is independently —

    H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    each R** is independently —

    H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;

    x is 0 or 1;

    y is 0, 1 or 2;

    each n is independently 0, 1, 2, or 3; and

    each p is independently 0, 1, or 2.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×